Effectiveness of a pharmacist intervention in patients with lung disease
Not Applicable
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Chronic obstructive pulmonary disease, unspecifiedRespiratory
- Registration Number
- ISRCTN32281812
- Lead Sponsor
- The Health Research Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
1. Physician-diagnosed COPD
2. Age =40 years at trial enrollment
3. Ability to answer questionnaires in English
Exclusion Criteria
1. Severe disease defined as a known Forced Expiratory Volume in 1 second (FEV1)/ Forced Vital Capacity (FVC) of <30%
2. A diagnosis of dementia or a prescription for cholinesterase inhibitors
3. A terminal illness
4. Participation in another clinical trial
5. Do not provide consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Medication adherence, measured as the proportion of days covered (PDC) at baseline and 6 months
- Secondary Outcome Measures
Name Time Method <br> Measured at baseline and 6 months:<br> 1. Quality of life, assessed by the St. George’s Respiratory Questionnaire (shorter version)<br> 2. Medication inhalation technique, measured using a pharmacist-scored scale<br> 3. Healthcare resource utilization (frequency of physician visits, hospitalizations, emergency department visits and pharmacy visits), reported by the patient at 6 months<br> 4. Antibiotic and oral corticosteroid use for acute exacerbations of COPD (AECOPD), reported by the patient at 6 months<br>